Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
At Electromedical Technologies, we believe results speak louder than words. Since ...
At Electromedical Technologies, we believe resu...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...
With operations in South San Francisco, CA and ...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Join the National Investor Network and get the latest information with your interests in mind.